Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.66 USD 1.92% Market Closed
Market Cap: 76.8m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Research & Development
-$64.2m
CAGR 3-Years
-101%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Aerovate Therapeutics Inc
Glance View

Market Cap
76.8m USD
Industry
Biotechnology

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

AVTE Intrinsic Value
4.24 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Aerovate Therapeutics Inc's Research & Development?
Research & Development
-64.2m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Research & Development amounts to -64.2m USD.

What is Aerovate Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-101%

Over the last year, the Research & Development growth was -66%. The average annual Research & Development growth rates for Aerovate Therapeutics Inc have been -101% over the past three years .

Back to Top